Molecular basis of group A streptococcal virulence

Lancet Infectious Diseases

Volumn 3, Issue 4, 2003, Pages 191-200

  Bisno, Alan L ^a,d   Brito, M O ^b   Collins, C M ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; BINDING PROTEIN; CYTOKINE; FIBRONECTIN; HYALURONIC ACID; M PROTEIN; STREPTOCOCCUS VACCINE; VIRULENCE FACTOR;

AMINO ACID SEQUENCE; BACTERIAL COLONIZATION; BACTERIAL GENOME; BACTERIAL MEMBRANE; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIUM ADHERENCE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG SAFETY; GENE FUNCTION; GENE STRUCTURE; GENETIC REGULATION; HUMAN; MOLECULAR BIOLOGY; NECROTIZING FASCIITIS; NONHUMAN; PATHOPHYSIOLOGY; PHAGOCYTOSIS; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; RHEUMATIC FEVER; SEQUENCE ANALYSIS; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PYOGENES; TECHNIQUE; TOXIC SHOCK SYNDROME;

STREPTOCOCCUS PYOGENES;

EID: 0037381631     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(03)00576-0     Document Type: Review

References (149)

1. O'Brien KL, Beall B, Barrett NL, et al. Epidemiology of invasive group A streptococcus disease in the United States, 1995-1999. Clin Infect Dis 2002; 35: 268-76.
2. Beachey EH, Stollerman GH, Chiang EY, Chiang TM, Seyer JM, Kang AH. Purification and properties of M protein extracted from group A streptococci with pepsin: covalent structure of the amino terminal region of type 24 M antigen. J Exp Med 1977; 145: 1469-83.
3. Fischetti VA. Streptococcal M protein. Sci Am 1991; 264: 58-65.
4. Fischetti VA. Surface proteins on Gram-positive bacteria. In: Fischetti VA, et al, eds. Washington DC: ASM Press, 2000: 11-24.
5. Facklam RF, Martin DR, Lovgren M, et al. Extension of the Lancefield classification for group A streptococci by addition of 22 new M protein gene sequence types from clinical isolates: emm103 to emm124. Clin Infect Dis 2002; 34: 28-38.
6. Musser JM, Kapur V, Szeto J, Pan X, Swanson DS, Martin DR. Genetic diversity and relationships among Streptococcus pyogenes strains expressing serotype M1 protein: recent intercontinental spread of a subclone causing episodes of invasive disease. Infect Immun 1995; 63: 994-1003.
7. Bisno AL. Alternate complement pathway activation by group A streptococci: role of M-protein. Infect Immun 1979; 26: 1172-76.
8. Horstmann RD, Sievertsen HJ, Knobloch J, Fischetti VA. Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc Natl Acad Sci USA 1988; 85: 1657-61.
9. Johnsson E, Berggard K, Kotarsky H, et al. Role of the hypervariable region in streptococcal M proteins: binding of a human complement inhibitor. J Immunol 1998; 161: 4894-901.
10. Kotarsky H, Gustafsson M, Svensson HG, Zipfel PF, Truedsson L, Sjobring U. Group A streptococcal phagocytosis resistance is independent of complement factor H and factor H-like protein 1 binding. Mol Microbiol 2001; 41: 817-26.
11. Berggard K, Johnsson E, Morfeldt E, Persson J, Stalhammar-Carlemalm M, Lindahl G. Binding of human C4BP to the hypervariable region of M protein: a molecular mechanism of phagocytosis resistance in Streptococcus pyogenes. Mol Microbiol 2001; 42: 539-51.
12. Perez-Caballero D, Alberti S, Vivanco F, Sanchez-Corral P, Rodriguez dC. Assessment of the interaction of human complement regulatory proteins with group A streptococcus. Identification of a high-affinity group A streptococcus binding site in FHL-1. Eur J Immunol 2000; 30: 1243-53.
13. Whitnack E, Beachey EH. Inhibition of complement-mediated opsonization and phagocytosis of Streptococcus pyogenes by D fragments of fibrinogen and fibrin bound to cell surface M protein. J Exp Med 1985; 162: 1983-97.
14. Dale JB, Washburn RG, Marques MB, Wessels MR. Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci. Infect Immun 1996; 64:1495-501.
15. Bisno AL. Management of streptococcal infections and prevention of rheumatic fever: the changing scene. In: Sande MA, Hudson LD, Root RK, eds. Contemporary issues in infectious diseases, vol 5. Respiratory infections. New York: Churchill Livingston; 1986: 217-34.
16. Penney TJ, Martin DR, Williams LC, de Malmanche SA, Bergquist PL. A single emm gene-specific oligonucleotide probe does not recognise all members of the Streptococcus pyogenes M type 1. FEMS Microbiol Lett 1995; 130: 145-50.
17. Musser JM, Kapur V, Szeto J, Pan X, Swanson DS, Martin DR. Genetic diversity and relationships among serotype M1 strains of Streptococcus pyogenes. Dev Biol Stand 1995; 85: 209-13.
18. de Malmanche SA, Martin DR. Protective immunity to the group A streptococcus may be only strain specific. Med Microbiol Immunol 1994; 183: 299-306.
19. Podbielski A, Schnitzler N, Beyhs P, Boyle MDP. M-related protein (Mrp) contributes to group A streptococcal resistance to phagocytosis by human granulocytes. Mol Microbiol 1996; 19: 429-41.
20. Ji Y, Schnitzler N, DeMaster E, Cleary P. Impact of M49, Mrp, Enn, and C5a peptidase proteins on colonization of the mouse oral mucosa by Streptococcus pyogenes. Infect Immun 1998; 66: 5399-405.
21. Dale JB, Chiang EY, Liu S, Courtney HS, Hasty DL. New protective antigen of group A streptococci. J Clin Invest 1999; 103: 1261-68.
22. Lei B, DeLeo FR, Hoe NP, et al. Evasion of human innate and acquired immunity by a bacterial homolog of CD 11 b that inhibits opsonophagocytosis. Nat Med 2001; 7: 1298-305.
23. Crater DL, van de Rijn I. Hyaluronic acid synthesis operon (has) expression in group A streptococci. J Biol Chem 1995; 270: 18452-58.
24. Alberti S, Ashbaugh CD, Wessels M. Structure of the has operon promoter and regulation of hyaluronic acid capsule expression in group A Streptococcus. Mol Microbiol 1998; 28: 343-53.
25. Ashbaugh CD, Alberti S, Wessels M. Molecular analysis of the capsule gene region of Group A Streptococcus: the has AB genes are sufficient for capsule expression. J Bacteriol 1998; 180: 4955-59.
26. Whitnack E, Bisno AL, Beachey EH. Hyaluronate capsule prevents attachment of group A streptococci to mouse peritoneal macrophages. Infect Immun 1981; 31: 985-91.
27. Wessels MR, Moses AE, Goldberg JB, DiCesare TJ. Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. Proc Natl Acad Sci USA 1991; 88: 8317-21.
28. Pilot I. The role of mucoid hemolytic streptococci in rheumatic fever and arthritis. Proceedings of the Central Society for Clinical Research 1944; 17: 70-71.
29. Stollerman GH. The nature of rheumatogenic streptococci. Mt Sinai J Med 1996; 63: 144-58.
30. Johnson DR, Stevens DL, Kaplan EL. Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis. J Infect Dis 1992; 166: 374-82.
31. Fillit HM, McCarty M, Blake M. Induction of antibodies to hyaluronic acid by immunization of rabbits with encapsulated streptococci. J Exp Med 1986; 164: 762-76.
32. Fillit HM, Blake M, MacDonald C, McCarty M. Immunogenicity of liposome-bound hyaluronate in mice: at least two different antigenic sites on hyaluronate are identified by mouse monoclonal antibodies. J Exp Med 1988; 168: 971-82.
33. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000; 13: 470-511.
34. Courtney HS, Hasty DL, Dale JB. Molecular mechanisms of adhesion, colonization, and invasion of group A streptococci. Ann Med 2002; 34: 77-87.
35. Beachey EH, Simpson WA. The adherence of group A streptococci to oropharyngeal cells: the lipoteichoic acid adhesin and fibronectin receptor. Infection 1982; 10: 107-11.
36. Ofek I, Beachey EH, Jefferson W, Campbell GL. Cell membrane-binding properties of group A streptococcal lipoteichoic acid. J Exp Med 1975; 187: 1161-67.
37. Dale JB, Baird RW, Courtney HS, Hasty DL, Bronze MS. Passive protection of mice against group A streptococcal pharyngeal infection by lipoteichoic acid. J Infect Dis 1994; 169: 319-23.
38. Hasty DL, Ofek I, Courtney HS, Doyle RJ. Multiple adhesins of streptococci. Infect Immun 1992; 60: 2147-52.
39. Ellen RP, Gibbons RJ. Parameters affecting the adherence and tissue tropisms of Streptococcus pyogenes. Inject Immun 1974; 9: 85-91.
40. Caparon MG, Stephens DS, Olsen A, Scott JR. Role of M protein in adherence of group A streptococci. Infect Immun 1991; 59: 1811-17.
41. Courtney HS, Bronze MS, Dale JB, Hasty DL. Analysis of the role of M24 protein in group A streptococcal adhesion and colonization by use of omega-interposon mutagenesis. Infect Immun 1994; 62: 4868-73.
42. Hollingshead SK, Simecka JW, Michalek SM. Role of M protein in pharyngeal colonization by group A streptococci in rats. Infect Immun 1993; 61: 2277-83.
43. Wang JR, Stinson MW. M protein mediates streptococcal adhesion to HEp-2 cells. Infect Immun 1994; 62: 442-48.
44. Courtney HS, Liu S, Dale JB, Hasty DL. Conversion of M serotype 24 of Streptococcus pyogenes to M serotypes 5 and 18: effect on resistance to phagocytosis and adhesion to host cells. Infect Immun 1997; 65: 2472-74.
45. Okada N, Pentland AP, Falk P, Caparon MG. M protein and protein F act as important determinants of cell-specific tropism of Streptococcuspyogenes in skin tissue. J Clin Invest 1994; 94: 965-77.
46. Okada N, Liszewski MK, Atkinson JP, Caparon M. Membrane cofactor protein (CD46) is a keratinocyte receptor for the M protein of the group A streptococcus. Proc Natl Acad Sci USA 1995; 92: 2489-93.
47. Hanski E, Caparon M. Protein F, a fibronectinbinding protein, is an adhesin of the group A streptococcus Streptococcus pyogenes. Proc Natl Acad Sci USA 1992; 89: 6172-76.
48. Talay SR, Valentin-Weigand P, Jerlstrom PG, Timmis KN, Chhatwal GS. Fihronectin-hinding protein of Streptococcus pyogenes: sequence of the binding domain involved in adherence of streptococci to epithelial cells. Infect Immun 1992; 60: 3837-44.
49. Kreikemeyer B, Talay SR, Chhatwal GS. Characterization of a novel fibronectin-binding surface protein in group A streptococci. Mol Microbiol 1995; 17: 137-45.
50. Courtney HS, Dale JB, Hasty DL. Differential effects of the streptococcal fibronectin-binding protein, FBP54, on adhesion of group A streptococci to human buccal cells and HEp-2 tissue culture cells. Infect Immun 1996; 64: 2415-19.
51. Jaffe J, Natanson-Yaron S, Caparon MG, Hanski E. Protein F2, a novel fibronectin-binding protein from Streptococcus pyogenes, possesses two binding domains. Mol Microbiol 1996; 21: 373-84.
52. Rocha CL, Fischetti VA. Identification and characterization of a novel fibronectin-binding protein on the surface of group A streptococci. Infect Immun 1999; 67: 2720-28.
53. Hanski E, Horwitz PA, Caparon MG. Expression of protein F, the fibronectin-binding protein of Streptococcus pyogenes JRS4, in heterologous streptococcal and enterococcal strains promotes their adherence to respiratory epithelial cells. Infect Immun 1992; 60: 5119-25.
54. Guzman CA, Talay SR, Molinari G, Medina E, Chhatwal GS. Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin-binding protein SfbI. J Infect Dis 1999; 179: 901-6.
55. Gibson C, Fogg G, Okada N, Geist RT, Hanski E, Caparon M. Regulation of host cell recognition in Streptococcus pyogenes. Dev Biol Stand 1995; 85: 137-44.
56. Caparon MG, Geist RT, Perez-Casal J, Scott JR. Environmental regulation of virulence in group A streptococci: transcription of the gene encoding M protein is stimulated by carbon dioxide. J Bacteriol 1992; 174: 5693-701.
57. Gibson C, Fogg G, Okada N, Geist RT, Hanski E, Caparon M. Regulation of host cell recognition in Streptococcus pyogenes. Dev Biol Stand 1995; 85: 137-44.
58. Ashbaugh CD, Moser TJ, Shearer MH, White GL, Kennedy RC, Wessels MR. Bacterial determinants of persistent throat colonization and the associated immune response in a primate model of human group A streptococcal pharyngeal infection. Cell Microbiol 2000; 2:283-92.
59. Wessels MR, Bronze MS. Critical role of the group a streptococcal capsule in pharyngeal colonization and infection in mice. Proc Natl Acad Sci USA 1994; 91: 12238-42.
60. LaPenta D, Rubens C, Chi E, Cleary PP. Group A streptococci efficiently invade human respiratory epithelial cells. Proc Natl Acad Sci USA 1994; 91: 12115-19.
61. Cue D, Dombek PE, Lam H, Cleary PP. Streptococcus pyogees serotype M 1 encodes multiple pathways for entry into human epithelial cells. Infect Immun 1998; 66: 4593-601.
62. Hagman MM, Dale JB, Stevens DL. Comparison of adherence to and penetration of a human laryngeal epithelial cell line by group A streptococci of various M protein types. FEMS Immunol Med Microbiol 1999; 23: 195-204.
63. Dombek PE, Cue D, Sedgewick J, et al. Highfrequency intracellular invasion of epithelial cells by serotype M1 group A streptococci: M1 protein-mediated invasion and cytoskeletal rearrangements. Mol Microbiol 1999; 31: 859-70.
64. Molinari G, Talay SR, Valentin-Weigand P, Rohde M, Chhatwal GS. The fibronectin-binding protein of Streptococcus pyogenes, SfbI, is involved in the internalization of group ofgroup A streptococci by epithelial cells The fibronectin-binding protein of Streptococcus pyogenes, SfbI, is involved in the internalization of group A streptococci by epithelial cells. Infect Immun 1997; 65: 1357-63.
65. Ozeri V, Rosenshine I, Mosher DF, Fassler R, Hanski E. Roles ofintegrins and fibronectin in the entry of Streptococcus pyogenes into cells via protein Fl. Mol Microbiol 1998; 30: 625-37.
66. Osterlund A, Engstrand L. Intracellular penetration and survival of Streptococcus pyogenes in respiratory epithelial cells in vitro. Acta Otolaryngol 1995; 115: 685-88.
67. Osterlund A, Engstrand L. An intracellular sanctuary for Streptococcuspyogenes in human tonsillar epithelium - studies of asymptomatic carriers and in vitro cultured biopsies. Acta Otolaryngol 1997; 117: 883-88.
68. Jadoun J, Eyal O, Sela S. Role of CsrR, hyaluronic acid, and SpeB in the internalization of Streptococcus pyogenes M type 3 strain by epithelial cells. Infect Immun 2002; 70: 462-69.
69. Darmstadt GL, Mentele L, Podbielski A, Rubens CE. Role of group A streptococcal virulence factors in adherence to keratinocytes. Infect Immun 2000; 68: 1215-21.
70. Schrager HM, Rheinwald JG, Wessels MR. Hyaluronic acid capsule and the role of streptococcal entry into keratinocytes in invasive skin infection. J Clin Invest 1996; 98: 1954-58.
71. Ashbaugh CD, Warren HB, Carey VJ, Wessels MR. Molecular analysis of the role of the group a streptococcal cysteine protease, hyaluronic acid capsule, and M protein in a murine model of human invasive soft-tissue infection. J Clin Invest 1998; 102: 550-60.
72. Schrager HM, Alberti S, Cywes C, Dougherty GJ, Wessels MR. Hyaluronic acid capsule modulates M protein-mediated adherence and acts as a ligand for attachment of group A streptococcus to CD44 on human keratinocytes. J Clin Invest 1998; 101: 1708-16.
73. Cywes C, Stamenkovic I, Wessels MR. CD44 as a receptor for colonization of the pharynx by group A Streptococcus. J Clin Invest 2000; 106: 995-1002.
74. Cywes C, Wessels MR. Group A streptococcus tissue invasion by CD44-mediated cell signalling. Nature 2001; 414: 648-52.
75. Madden JC, Ruiz N, Caparon M. Cytolysin-mediated translocation (CMT): a functional equivalent of type III secretion in gram-positive bacteria. Cell 2001; 104: 143-52.
76. Dale JB, Chiang EY, Hasty DL, Courtney HS. Antibodies against a synthetic peptide of Saga neutralize the cytolytic activity of streptolysin S from group A streptococci. Infect Immun 2002; 70: 2166-70.
77. Carr A, Sledjeski DD, Podbielski A, Boyle MD, Kreikemeyer B. Similarities between complement-mediated and streptolysin S-mediated hemolysis. J Biol Chem 2001; 276: 41790-96.
78. Yinduo J, McLandshorough L, Kondagunta A, Cleary PP. C5a peptidase alters clearance and trafficking of group A streptococci by infected mice. Infect Immun 1996; 64: 503-10.
79. Wexler DE, Chenoweth DE, Cleary PP. Mechanism of action of the group A streptococcal C5a inactivator. Proc Natl Acad Sci USA 1985; 82: 8144-48.
80. Fernie-King BA, Seilly DJ, Davies A, Lachmann PJ. Streptococcal inhibitor of complement inhibits two additional components of the mucosal innate immune system: secretory leukocyte proteinase inhibitor and lysozyme. Infect Immun 2002; 70: 4908-16.
81. Fernie-King BA, Seilly DJ, Willers C, Wurzner R, Davies A, Lachmann PJ. Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes. Immunology 2001; 103: 390-98.
82. Hoe NP, Ireland RM, DeLeo FR, et al. Insight into the molecular basis of pathogen abundance: group A streptococcus inhibitor of complement inhibits bacterial adherence and internalization into human cells. Proc Natl Acad Sci USA 2002; 99: 7646-51.
83. Baker M, Gutman DM, Papageorgiou AC, Collins CM, Acharya KR. Structural features of a zinc binding site in the superantigen strepococcal pyrogenic exotoxin A (SpcA1): implications for MHC class II recognition. Protein Sci 2001; 10: 1268-73.
84. Unnikrishnan M, Altmann DM, Proft T, et al. The bacterial superantigen streptococcal mitogenic exotoxin Z is the major immunoactive agent of Streptococcus pyogenes. J Immunol 2002; 169: 2561-69.
85. Smoot LM, McCormick JK, Smoot JC, et al. Characterization of two novel pyrogenic toxin superantigens made by an acute rheumatic fever clone of Streptococcus pyogenes associated with multiple disease outbreaks. Infect Immun 2002; 70: 7095-104.
86. Papageorgiou AC, Collins CM, Gutman DM, et al. Structural basis for the recognition ofsuperantigen streptococcal pyrogenic exotoxin A (SpeA1) by MHC class II molecules and T-cell receptors. EMBO J 1999; 18: 9-21.
87. Roussell A, Anderson BF, Baker HM, Fraser JD, Baker EN. Crystal structure of the streptococcal superantigen Spe C: dimerization and zinc-binding suggest a novel mode of interaction with MHC class II molecules. Nat Struct Biol 2002; 4: 635-43.
88. Arcus VL, Proft T, Sigrell JA, Baker HM, Fraser JD, Baker EN. Conservation and variation in superantigen structure and activity highlighted by the three-dimensional structures of two new superantigens from Streptococcus pyogenes. J Mol Biol 2000; 299: 157-68.
89. Papageorgiou AC, Acharya KR. Microbial superantigens: from structure to function. Trends Microbiol 2000; 8: 369-75.
90. Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science 1990; 248: 705-11.
91. Manders SM. Toxin-mediated streptococcal and staphylococcal disease. J Am Acad Dermatol 1999; 39: 383-98.
92. Bohach GA, Fast DJ, Nelson RD, Schlievert PM. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. CRC Crit Rev Microbiol 1990; 17: 251-72.
93. Hauser AR, Stevens DL, Kaplan EL, Schlievert PM. Molecular analysis of pyrogenic exotoxins from Streptococcus pyogenes isolates associated with toxic shock-like syndrome. J Clin Microbiol 1991; 29: 1562-67.
94. Collin M, Olsen A. Effect of SpeB and EndoS from Streptococcus pyogenes on human immunoglobulins. Infect Immun 2001; 69: 7187-89.
95. Kapur V, Majesky MW, Li LL, Black RA, Musser JM. Cleavage ofinterleukin Ibeta (IL-1beta) precursor to produce active IL-lbeta by a conserved extracellular cysteine protease from Streptococcus pyogenes. Proc Natl Acad Sci USA 1993; 90: 7676-80.
96. Herwald H, Collin M, Muller-Esterl W, Bjorck L. Streptococcal cysteine proteinase releases kinins: a novel virulence mechanism. J Exp Med 1996; 184: 665-73.
97. Watanabe Y, Todome Y, Ohkuni H, et al. Cysteine protease activity and histamine release from the uman mast cell line HMC-1 stimulated by recombinant streptococcal pyrogenic exotoxin B/streptococcal cysteine protease. Infect Immun 2002; 70: 3944-47.
98. Lukomski S, Burns EHJ, Wyde PR, et al. Genetic inactivation of an extracellular cysteine protease (SpeB) expressed by Streptococcus pyogenes decreases resistance to phagocytosis and dissemination to organs. Infect Immun 1998; 66: 771-76.
99. Saouda M, Wu W, Conran P, Boyle MD. Streptococcal pyrogenic exotoxin B enhances tissue damage initiated by other Streptococcus pyogenes products. J Infect Dis 2001; 184: 723-31.
100. Kuo CF, Wu JJ, Lin KY, et al. Role of streptococcal pyrogenic exotoxin B in the mouse model of group A streptococcal infection. Infect Immun 1998; 66: 3931-35.
101. Kansal RG, McGeer A, Low DE, Norrby-Teglund A, Kotb M. Inverse relation between disease severity and expression of the streptococcal cysteine protease, SpeB, among clonal M1T1 isolates recovered from invasive group A streptococcal infection cases. Infect Immun 2000; 68: 6362-69.
102. Rasmussen M, Bjorck L. Proteolysis and its regulation at the surface of Streptococcus pyogenes. Mol Microbiol 2002; 43: 537-44.
103. Norrby-Teglund A, Norrby SR, Low DE. The treatment of severe group A streptococcal infections. Curr Infect Dis Rep 2003; 5: 28-37.
104. Hackett SP, Stevens DL. Streptococcal toxic shock syndrome: synthesis of tumor necrosis factor and interleukin-1 by monocytes stimulated with pyrogenic exotoxin A and streptolysin O. J Infect Dis 1992; 165: 879-85.
105. Sriskandan S, Cohen J. Gram-positive sepsis. Mechanisms and differences from gram-negative sepsis. Infect Dis Clin North Am 1999; 13: 397-412.
106. Basma H, Norrby-Teglund A, Guedez Y, et al. Risk factors in the pathogenesis of invasive group A streptococcal infections: role of protective humoral immunity. Infect Immun 1999; 67: 1871-77.
107. Norrby-Teglund A, Chatellier S, Low DE, McGeer A, Green K, Kotb M. Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection. Eur J Immunol 2000; 30: 3247-55.
108. Kotb M, Norrby-Teglund A, McGeer A, et al. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med 2002; 8:1398-404.
109. Ferretti JJ, McShan WM, Ajdic D, et al. Complete genome sequence of an M1 strain of Streptococcus pyogenes 1. Proc Natl Acad Sci USA 2001; 98: 4658-63.
110. Beres SB, Sylva GL, Barbian KD, et al. Genome sequence ofa serotype M3 strain of group A streptococcus: phage-encoded toxins, the high-virulence phenotype, and clone emergence. Proc Natl Acad Sci USA 2002; 99: 10078-83.
111. Smoot JC, Barbian KD, Van Gompel JJ, et al. Genome sequence and comparative microarray analysis ofserotype M18 group A Streptococcus strains associated with acute rheumatic fever outbreaks. Proc Natl Acad Sci USA 2002; 99: 4668-73.
112. Wagner PL, Waldor MK. Bacteriophage control of bacterial virulence. Infect Immun 2002; 70: 3985-93.
113. Perez-Casal J, Caparon MG, Scott JR. Mry, a transacting positive regulator of the M protein gene of Streprococcus pyogenes with similarity to the receptor proteins of two-component regulatory systems. J Bacteriol 1991; 173: 2617-24.
114. Levin JC, Wessels MR. Identification of csrR/csrS, a genetic locus that regulates hyaluronic acid capsule synthesis in group A Streptococcus. Mol Microbiol 1998; 30: 209-19.
115. Federle MJ, McIver KS, Scott JR. A response regulator that represses transcription of several virulence operons in the group A streptococcus. J Bacteriol 1999; 181: 3649-57.
116. Heath A, DiRita VJ, Barg NL, Engleberg NC. A two-component regulatory system, CsrR-CsrS, represses expression of three Streptococcus pyogenes virulence factors, hyaluronic acid capsule, streptolysin S, and pyrogenic exotoxin B. Infect Immun 1999; 67: 5298-305.
117. Okada N, Geist RT, Caparon MG. Positive transcriptional control of mry regulates virulence in the group A streptococcus. Mol Microbiol 1993; 7: 893-903.
118. McIver KS, Myles RL. Two DNA-binding domains of Mga are required for virulence gene. Mol Microbiol 2002; 43: 1591-601.
119. Van Heyningen T, Fogg G, Yates D, Hanski E, Caparon M. Adherence and fibrinectin binding are environmentally regulated in the group A streptococci. Mol Microbiol 1993; 9: 1213-22.
120. Fogg GC, Gibson CM, Caparon MG. The identification of rofA, a positive-acting regulatory component of prtF expression: use of an m-gamma-delta-based shuttle mutagenesis strategy in Streptococcus pyogenes. Mol Microbiol 1994; 11: 671-84.
121. Podbielski A, Woischnik M, Leonard BA, Schmidt KH. Characterization of nra, a global negative regulator gene in group A streptococci. Mol Microbiol 1999; 31: 1051-64.
122. Miller AA, Engleberg NC, DiRita VJ. Repression of virulence genes by phosphorylation-dependent oligomerization of CsrR at target promoters in S pyogenes. Mol Microbiol 2001; 40:976-90.
123. Federle MJ, Scott JR. Identification of binding sites for the group A streptococcal global regulator CovR. Mol Microbiol 2002; 43: 1161-72.
124. Graham MR, Smoot LM, Migliaccio CA, et al. Virulence control in group A streptococcus by a two-component gene regulatory system: global expression profiling and in vivo infection modeling. Proc Natl Acad Sci USA 2002; 99: 13855-60.
125. Chaussee MS, Sylva GL, Sturdevant DE, et al. Rgg influences the expression of multiple regulatory loci to coregulate virulence factor expression in Streptococcus pyogenes. Infect Immun 2002; 70: 762-70.
126. Lyon WR, Gibson CM, Caparon MG. A role for trigger factor and an rgg-like regulator in the transcription, secretion and processing of the cysteine proteinase of Streptococcus pyogenes. EMBO J 1998; 17: 6263-75.
127. Kreikemeyer B, Boyle MD, Buttaro BA, Heinemann M, Podbielski A. Group A streptococcal growth phase-associated virulence factor regulation by a novel operon (Fas) with homologies to two-component-type regulators requires a small RNA molecule. Mol Microbiol 2001; 39: 392-406.
128. Li Z, Sledjeski DD, Kreikemeyer B, Podbielski A, Boyle MD. Identification of pel, a Streptococcus pyogenes locus that affects both surface and secreted proteins. J Bacteriol 1999; 181: 6019-27.
129. Hidalgo-Grass C, Ravins M, Dan-Goor M, Jaffe J, Moses AE, Hanski E. A locus of group A streptococcus involved in invasive disease and DNA transfer. Mol Microbiol 2002; 46: 87-99.
130. Stollerman GH. Rheumatic fever in the 21st century. Clin Infect Dis 2001; 33: 806-14.
131. Bisno AL. The concept of rheumatogenic and non-rheumatogenic group A streptococci. In: Read SE, Zabriskie JB, eds. Streptococcal diseases and the immune response. New York: Academic Press; 1980: 789-803.
132. Smoot JC, Korgenski EK, Daly JA, Veasy LG, Musser JM. Molecular analysis of group A Streptococcus type emm18 isolates temporally associated with acute rheumatic fever outbreaks in Salt Lake City, Utah. J Clin Microbiol 2002; 40: 1805-10.
133. Bessen DE, Fischetti VA. Differentiation between two biologically distinct classes of group A streptococci by limited substitutions of amino acids within the shared region of M protein-like molecules. J Exp Med 1990; 172: 1757-64.
134. Bessen DE, Veasy LG, Hill HR, Augustine NH, Fischetti VA. Serologic evidence for a class I group A streptococcal infection among rheumatic fever patients. J Infect Dis 1995; 172: 1608-11.
135. Barnham M, Thornton TJ, Lange K. Nephritis caused by Streptococcus zooepidemicus (Lancefield group C). Lancet 1983; 1: 945-48.
136. Lange CF. Chemistry of cross-reactive fragments of streptococcal cell membrane and human glomerular basement membrane. Transplant Proc 1969; 1: 959-63.
137. Goroncy-Bermes P, Dale JB, Beachey EH, Opferkuch W. Monoclonal antibody to human renal glomeruli cross-reacts with streptococcal M protein. Infect Immun 1987; 55: 2416-19.
138. Lindberg LH, Vosti KL. Elution of glomerular bound antibodies in experimental streptococcal glomerulonephritis. Science 1969; 166: 1032-33.
139. Markowitz AS, Horn D, Aseron C, Novak R, Battiforia HA. Streptococcal related glomerulonephritis 3. Glomerulonephritis in rhesus monkeys immunologically induced both actively and passively with a soluble fraction from nephritogenic streptococcal protoplasmic membranes. J Immunol 1971; 107: 504-11.
140. Cu GA, Mezzano S, Bannan JD, Zabriskie JB. Immunohistochemical and serological evidence for the role of Streptococcal proteinase in acute post-streptococcal glomerulonephritis. Kidney Int 1999; 54: 819-26.
141. Lange K, Ahmed U, Kleinberger H, Treser G. A hitherto unknown streptococcal antigen and its probable relation to acute poststreptococcal glomerulonephritis. Clin Nephrol 1976; 5: 207-15.
142. Yoshizawa N, Oshima S, Sagel I, Shimizu J, Treser G. Role of a streptococcal antigen in the pathogenesis of acute poststreptococcal glomerulonephritis. J Immunol 1992; 148: 3110-16.
143. Johnson KH, Zabriskie JB. Purification and partial characterization of the nephritis strain-associated protein from Streptococcuspyogenes, group A. J Exp Med 1986; 163: 697-712.
144. Nordstrand A, Norgren M, Ferretti JJ, Holm SE. Streptokinase as a mediator of acute post-streptococcal glomerulonephritis in an experimental mouse model. Infect Immun 1998; 66: 315-21.
145. Mezzano S, Burgos E, Mahabir R, Kemeny E, Zabriskie JB. Failure to detect unique reactivity to streptococcal streptokinase in either the sera or renal biopsy specimens of patients with acute poststreptococcal glomerulonephritis. Clin Nephrof 1992; 38: 305-10.
146. Dale JB. Multivalent group A streptococcal vaccines. In: Stevens DL, Kaplan EL, eds. Streptococcal infections: clinical aspects, microbiology, and molecular pathogenesis. New York: Oxford University Press, 2000: 390-401.
147. Hu MC, Walls MA, Stroop SD, Reddish MA, Beall B, Dale JB. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 2002; 70: 2171-77.
148. Fischetti VA. Vaccine approaches to protect against group A streptococcal pharyngitis. In: Fischetti VA, et al, eds. Gram-positive pathogens. Washington, DC: American Society for Microbiology, 2000: 96-104.
149. Fischetti VA. Protection against group A streptococcal infection. In: Stevens DL, Kaplan EL, eds. Streptococcal infections: clinical aspects, microbiology, and molecular pathogenesis. New York: Oxford University Press, 2000: 371-89.